The Annual Meeting of the American Society of Clinical Oncology (ASCO) was held from May 31 to June 4, 2024, in Chicago, IL. This event serves as a pivotal gathering for healthcare professionals committed to enhancing patient care and outcomes within the field of oncology.

A prominent topic of discussion at ASCO24 was lung cancer. According to the Centers for Disease Control and Prevention (CDC), in 2020, there were 197,453 new cases of lung and bronchus cancer reported in the United States, with 136,084 resulting in fatalities. This equates to 47 new cases and 32 deaths per 100,000 individuals.

Outlined below are concise summaries of studies presented at ASCO24 that focus on advancing the most effective treatment options for managing lung cancer, including Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC), both early and metastatic:

  • Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer
  • Links
  • Key Takeaways
    • The researchers conducted a large-scale comparative effectiveness trial of early palliative care delivered via secure video versus in-person visits for patients with advanced non-small cell lung cancer (NSCLC) and their caregivers.
    • Early Palliative Care through video conferencing versus in-person visits showed similar effects on the Quality of Life (QOL) of patients with advanced NSCLC. Additionally, there were no significant differences in various patient-reported outcomes between the two modalities. However, it was noted that caregivers were more likely to attend in-person visits vs video visits.
  • Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial
  • Links
  • Key Takeaways
    • The PALOMA-3 clinical trial compared the subcutaneous administration of Amivantamab (ami) and lazertinib (laz) to the intravenous (IV) administration of ami and laz in patients with EGFR Ex19del or L858R-mutated advanced NSCLC who had experienced disease progression on osimertinib and platinum-based chemotherapy. 
    • The subcutaneous administration of amikacin (SC ami) showed comparable pharmacokinetics and overall response rate when compared to IV administration. Surprisingly, the duration of response, progression-free survival, and overall survival were all longer in the SC arm compared to the IV arm, suggesting that the route of administration or formulation may impact treatment outcomes.
  • ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC) 
  • Links
  • Key Takeaways
    • The ADRIATIC study (NCT03703297) is a phase 3, randomized, double-blind, placebo-controlled, multicenter global study. It evaluated the use of durvalumab (D) plus tremelimumab (T) as consolidation therapy for patients with limited-stage small cell lung cancer (LS-SCLC) who had not experienced progression after concurrent chemoradiotherapy (cCRT).
    • The use of consolidation therapy with drug D following concurrent chemoradiotherapy (cCRT) has shown a statistically significant and clinically meaningful improvement in overall survival and progression-free survival when compared to a placebo in patients with LS-SCLC.
  • Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study 
  • Links
  • Key Takeaways
    • The Phase 3 LAURA study is a global, double-blind, placebo-controlled trial. This study evaluated the efficacy and safety of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC who did not experience progression after definitive chemoradiotherapy.
    • Following definitive CRT, Osimertinib showed a statistically significant and clinically meaningful improvement in progression-free survival for patients with unresectable stage III EGFR-mutated NSCLC, with no unexpected safety concerns.
  • Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study 
  • Links
  • Key Takeaways
    • Lorlatinib has shown enhanced progression-free survival and intracranial (activity compared to crizotinib in the phase 3 CROWN study involving treatment-naïve patients with advanced ALK+ NSCLC. The study showed long-term efficacy and safety results following 5 years of follow-up.
    • After 5 years of follow-up, the median progression-free survival in the lorlatinib arm has not yet been reached, marking the longest progression-free survival ever reported in advanced NSCLC.
  • KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
  • Links
  • Key Takeaways
    • The KRYSTAL-12 study is a randomized, open-label phase 3 trial comparing adagrasib (ADA) to docetaxel (DOCE) in patients with KRASG12C-mutated locally advanced or metastatic NSCLC. These patients have previously undergone platinum-based chemotherapy, either concurrently or sequentially with anti-PD-(L)1 therapy. This study aims to evaluate the efficacy of ADA in this patient population.
    • The results of the KRYSTAL-12 trial show that ADA has proven to be significantly more effective than DOCE in improving progression-free survival and overall response rate in patients with previously treated NSCLC that carries the KRASG12C mutation. This finding is not only statistically significant but also clinically meaningful, highlighting the potential of ADA as a promising treatment option for this patient population.
  • First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumor
  • Links
  • Key Takeaways
    • ABBV-706 is an Antibody-Drug Conjugate (ADC) that targets SEZ6, conjugated to a topoisomerase 1 inhibitor payload at a drug-to-antibody ratio of 6. This innovative treatment has shown high efficacy in preclinical models of Small Cell Lung Cancer (SCLC), Neuroendocrine Neoplasms (NENs), and Central Nervous System (CNS) tumors. The researchers report the results from the dose escalation (DE) study of ABBV-706 monotherapy.
    • ABBV-706 exhibited a well-tolerated safety profile and showed encouraging effectiveness in SCLC and neuroendocrine neoplasms.
  • Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial
  • Links
  • Key Takeaways
    • Lorlatinib is a powerful third-generation tyrosine kinase inhibitor (TKI) that effectively targets ROS1 and ALK, making it a promising treatment option for patients with advanced ROS1-positive NSCLC who have not previously received TKI therapy. Researchers evaluated the antitumor activity and safety profile of lorlatinib in this patient population.
    • Lorlatinib demonstrated long-lasting clinical efficacy in patients with TKI naive, advanced ROS1-positive NSCLC, including individuals with central nervous system metastases.
  • A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study
  • Links
  • Key Takeaways
    • The WU-KONG1 study was conducted to evaluate the efficacy of sunvozertinib (DZD9008) in patients with pre-treated NSCLC harboring EGFR exon 20 insertion mutations (exon20ins).
    • Sunvozertinib has shown promising antitumor effectiveness in NSCLC patients who have been previously treated with platinum and have EGFR exon20ins mutations. Additionally, it has exhibited a manageable safety profile.
  • Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001)
  • Links
  • Key Takeaways
    • Sigvotatug vedotin (SV), previously known as SGN-B6A, is an antibody-drug conjugate (ADC) that targets IB6 and has shown promising results in NSCLC in the Phase 1 study SGNB6A-001.  The latest findings are presented on the effectiveness and safety of SV in NSCLC.
    • SV consistently shows promising antitumor effects and a well-tolerated safety profile in patients with NSCLC.

Thank you for joining us for this recap of the ASCO24. We recommend visiting this link to explore the entirety of these posters as well as the other 2,000 posters that were showcased during the exciting event.

Copyright © 2024 Guideline Central, All rights reserved.